Skip to main content

February 2017, Vol 7, No 2

Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York. Read More ›

This detailed article of codes related to kidney cancers is intended to assist practice managers and other healthcare providers and payers to ensure the proper use of coding and billing information associated with the treatment of patients with kidney cancers. Read More ›

Page 1 of 2